ZhenGe Biotech
Latest round
- Series C
Last raised
- Aug 2022
Total raised
- $236M
Investors
- 20
About ZhenGe Biotech
Based in China, founded in 2017, ZhenGe Biotech is a macromolecular biopharmaceuticals developer that focuses CDMO services for macromolecular biopharmaceuticals, development and production of mammalian cell culture media, etc. In 2018, Shanghai Zhangjiang company provided one-stop CDMO service.,Ltd was recognized as a high-tech enterprise.,Ltd., Ltd. opened a new era of ADC business. In September 2020, Lingang Blue Bay 2000LX 3/5000LX 3 GM standard commercial production base started. In November 2020, Lingang Blue Bay 200LX 21500LX 1 GMP standard pilot production line was put into operation for 200 tons per year; GMp standard medium production line was put into operation. In February 2021, Shanghai ZhenGe Biotechnology Co. Ltd.5 g/L, which was an industry record. Later, it developed the PD-1 antibody production process for Junshi Bio, and created the record of the shortest process development cycle.5 g/L), the amplification and production consistency is good, and the end cell viability is good. The high rate is an important manifestation of the advantages of Zhenge Biotechnology. The core business of Zhenge Biology is CDMO service for macromolecular biopharmaceuticals, development and production of mammalian cell culture media including: drug-ready analysis of macromolecular drugs, CMC clinical application package for macromolecular drugs, cell line development, process development and optimization, pilot production, clinical sample production and commercial CMO services, process characterization and verification research, drug analysis Services, cell culture medium formulation development and commercial production, etc.
Who invested in ZhenGe Biotech
20 investors across 4 rounds
See all investors in ZhenGe Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ZhenGe Biotech
Who invested in ZhenGe Biotech?
ZhenGe Biotech has 20 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ZhenGe Biotech raised?
ZhenGe Biotech has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did ZhenGe Biotech last raise money?
ZhenGe Biotech's most recent round on record is a Series C, in Aug 2022.
What does ZhenGe Biotech do?
Based in China, founded in 2017, ZhenGe Biotech is a macromolecular biopharmaceuticals developer that focuses CDMO services for macromolecular biopharmaceuticals, development and production of mammalian cell culture media, etc.
Where is ZhenGe Biotech headquartered?
ZhenGe Biotech is headquartered in Shanghai, China.
Which VCs invest in companies like ZhenGe Biotech?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at ZhenGe Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like ZhenGe Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.